JAKARTA – PT Sarana Meditama Metropolitan Tbk (SAME) saw an 11.43% rise in revenue, but net profit contracted by 3.22% over the course of 2024 compared to 2023. The Inpatient Room segment contributed the highest percentage growth among its business segments.

In the 2024 financial report published on Monday (17/3), Jusup Halimi, President Director of SAME, stated that the company achieved revenue of IDR 1.70 trillion, up from IDR 1.53 trillion in 2023.

The largest revenue contributor came from the Medical Support segment, but the Inpatient Room segment showed the highest percentage growth.

The Medical Support segment generated IDR 1.05 trillion, up 9.45% from IDR 946.67 billion, while the Inpatient Room segment brought in IDR 398.01 billion, surging 24.37% from IDR 320.68 billion.

Meanwhile, the Outpatient segment contributed IDR 99.40 billion, declining 10% from IDR 110.01 billion, followed by the Administrative segment with IDR 87.50 billion, an 8.75% increase from IDR 80.66 billion. The Other segment brought in IDR 62 billion, down 15.06% from IDR 71.61 billion.

The company’s gross profit margin reached 30.12% in 2024, a slight rise from 29.98%. Operating profit also surged 117.02% to IDR 102.42 billion from IDR 47.32 billion, while profit for the year grew 16.13% to IDR 20.50 billion from IDR 17.42 billion. This growth was driven by rising financial expenses and income tax expenses.

However, net profit ultimately recorded a decline, coming in at IDR 11.84 billion, down from IDR 12.25 billion.

On the other hand, SAME’s stock fell 1.35%, or IDR 4, to IDR 292 at 13:30 WIB on Monday (17/3). It opened at IDR 296, with a peak price of IDR 304 and a low of IDR 278 per share.

Over the past week, SAME’s stock dropped 5.81%, or IDR 18, while it fell 4.58%, or IDR 14, over the past month. However, the stock has still risen 12.02%, or IDR 32, year-to-date (YTD) since the start of 2025. (LK/ZH)